[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334908-105":59,"doc-detail-334908-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-drug-repurposing-study-identifies-novel-foxm1-inhibitors-with-in-vitro-activity-against-breast-cancer-cells-abstract","A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells - Abstract","","FOXM1 is a proto-oncogenic transcription factor that drives cancer development and contributes to treatment resistance, especially in breast cancer. The study sought FOXM1 inhibitors by computational screening of drug databases, followed by in vitro validation against breast cancer cells. Pharmacophore modeling used the FOXM1 inhibitor FDI-6, then virtual screening was performed on DrugBank and Selleckchem. Molecular docking and crystal-structure pre-processing supported interaction assessment, while MTT cytotoxicity assays and Western blotting evaluated cellular and protein-level effects. Pantoprazole and Rabeprazole emerged as promising FOXM1 inhibitors, with molecular dynamics confirming stable FOXM1 binding. In vitro experiments showed strong FOXM1 inhibition at effective concentrations and reduced cell proliferation, supporting FOXM1-targeted therapy potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-drug-repurposing-study-identifies-novel-foxm1-inhibitors-with-in-vitro-activity-against-breast-cancer-cells-abstract/334908/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-drug-repurposing-study-identifies-novel-foxm1-inhibitors-with-in-vitro-activity-against-breast-cancer-cells-abstract/334908.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study?","Question",{"text":112,"@type":113},"To identify potential FOXM1 inhibitors by computational screening of drug databases and then validate their inhibitory activity against breast cancer cells in vitro.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which drugs were identified as potential FOXM1 inhibitors?",{"text":117,"@type":113},"Pantoprazole and Rabeprazole were identified through in silico screening and molecular docking, and further supported by in vitro results.",{"name":119,"@type":110,"acceptedAnswer":120},"How was FOXM1 inhibition evaluated experimentally?",{"text":121,"@type":113},"In vitro cytotoxicity was assessed using MTT assays, and Western blot analysis was used to evaluate protein expression levels alongside molecular docking and molecular dynamics evidence.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334908,1790172767,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Medical Oncology (2024) 41:188  \n[https://doi.org/10.1007/s12032-024-02427-0](https://doi.org/10.1007/s12032-024-02427-0)  \nA drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells  \nKhaled A. N. Abusharkh1,2,3 · Ferah Comert Onder4 · Venhar Çınar5 · Zuhal Hamurcu5 · Bulent Ozpolat6 · Mehmet Ay2  \nReceived: 21 April 2024 / Accepted: 10 June 2024 / Published online: 25 June 2024 © The Author(s) 2024  \nAbstract  \nFOXM1, a proto-oncogenic transcription factor, plays a critical role in cancer development and treatment resistance in cancers, particularly in breast cancer. Thus, this study aimed to identify potential FOXM1 inhibitors through computational screening of drug databases, followed by in vitro validation of their inhibitory activity against breast cancer cells. In silico studies involved pharmacophore modeling using the FOXM1 inhibitor, FDI-6, followed by virtual screening of DrugBank and Selleckchem databases. The selected drugs were prepared for molecular docking, and the crystal structure of FOXM1 was pre-processed for docking simulations. In vitro studies included MTT assays to assess cytotoxicity, and Western blot analysis to evaluate protein expression levels. Our study identified Pantoprazole and Rabeprazole as potential FOXM1 inhibitors through in silico screening and molecular docking. Molecular dynamics simulations confirmed stable interactions of these drugs with FOXM1 . In vitro experiments showed both Pantoprazole and Rabeprazole exhibited strong FOXM1 inhibition at effective concentrations and that showed inhibition of cell proliferation. Rabeprazole showed the inhibitor activity at 10 µM in BT-20 and MCF-7 cell lines. Pantoprazole exhibited FOXM1 inhibition at 30 µM and in BT-20 cells and at 70 µMin MCF-7 cells, respectively. Our current study provides the first evidence that Rabeprazole and Pantoprazole can bind to FOXM1 and inhibit its activity and downstream signaling, including eEF2K and pEF2, in breast cancer cells. These findings indicate that rabeprazole and pantoprazole inhibit FOXM1 and breast cancer cell proliferation, and they can be used for FOXM1-targeted therapy in breast or other cancers driven by FOXM1 .  \nGraphical Abstract  \nExtended author information available on the last page of the article  \nKeywords FOXM1 · Breast cancer · Triple-negative breast cancer · Drug repurposing · Rabeprazole · Pantoprazole · Molecular docking · Pharmacophore · Targeted therapy · Cell cytotoxicity assay · FOXM1-siRNA transfection · Western blot  \nAbbreviations  \n2D Two-dimensional  \n3D Three-dimensional  \nADME Absorption, distribution, metabolism, and excretion  \nDBD DNA-binding domain ER Estrogen receptor  \neEF2K Eukaryotic elongation factor 2 kinase FDA Food and drug administration FDI-6 Fork domain inhibitor-6  \nFOXM1 Forkhead box protein M1 FOX Forkhead box  \nHER2 Human epidermal growth factor receptor 2 MD Molecular dynamics  \nPDB Protein data bank  \npEF2 Phospho-eukaryotic elongation factor 2  \nRMSF Root-mean-square fluctuation RMSD Root-mean-square deviation SPC Simple point charge  \nTNBC Triple-negative breast cancer  \nIntroduction  \nBreast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer-related death [1, 2] . Triple-negative breast cancer (TNBC) accounts for approximately 10–20% of all breast cancers and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This subtype of breast cancer is known for its heterogeneous phenotypic structure, aggressive clinical course, and highly invasive nature, leading to early metastasis and poor prognosis. TNBC patients have shorter survival rates compared to those with other breast cancer subtypes, largely due to its resistance to current treatmentsand the lack of effective targeted therapies [3–6] . Although a new targeted treatment strategy, Sacituzumab, a Trop- 2-recepto","cbCaisHvYddadWPC","https://ap.wps.com/l/cbCaisHvYddadWPC","pdf",1994793,14,"English","# Abstract\n# Keywords\n# Abbreviations\n# Introduction","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To identify potential FOXM1 inhibitors by computational screening of drug databases and then validate their inhibitory activity against breast cancer cells in vitro.\"},{\"question\":\"Which drugs were identified as potential FOXM1 inhibitors?\",\"answer\":\"Pantoprazole and Rabeprazole were identified through in silico screening and molecular docking, and further supported by in vitro results.\"},{\"question\":\"How was FOXM1 inhibition evaluated experimentally?\",\"answer\":\"In vitro cytotoxicity was assessed using MTT assays, and Western blot analysis was used to evaluate protein expression levels alongside molecular docking and molecular dynamics evidence.\"}]","A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells - Abstract | PDF",1790008797,35]